Last reviewed · How we verify
Prophylaxis with valganciclovir plus everolimus
Valganciclovir is an antiviral medication that inhibits viral DNA synthesis, while everolimus is an immunosuppressant that inhibits mTOR signaling.
Valganciclovir is an antiviral medication that inhibits viral DNA synthesis, while everolimus is an immunosuppressant that inhibits mTOR signaling. Used for Prophylaxis of cytomegalovirus (CMV) infection in transplant patients, Prevention of organ rejection in transplant patients.
At a glance
| Generic name | Prophylaxis with valganciclovir plus everolimus |
|---|---|
| Sponsor | University of Bologna |
| Drug class | Antiviral, immunosuppressant |
| Target | DNA polymerase, mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology, Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Valganciclovir works by inhibiting the viral DNA polymerase, which is essential for viral replication. Everolimus, on the other hand, inhibits the mammalian target of rapamycin (mTOR) pathway, which plays a crucial role in cell growth and proliferation. By combining these two mechanisms, valganciclovir plus everolimus can potentially prevent the activation of latent viruses and reduce the risk of organ rejection in transplant patients.
Approved indications
- Prophylaxis of cytomegalovirus (CMV) infection in transplant patients
- Prevention of organ rejection in transplant patients
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Anemia
Key clinical trials
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (PHASE1)
- Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: